Print | Email | Share | Comments (0)

Dude! Marijuana Could Be the Basis for a Type 2 Drug

Jul 5, 2009

Scientists are researching cannabinoids—chemical compounds derived from marijuana—in the treatment of type 2 diabetes.

UK-based GW Pharmaceuticals has entered into a strategic alliance with Professor Mike Cawthorne and the Clore Laboratory, University of Buckingham, to research the use of cannabinoids-chemical compounds derived from marijuana-in the treatment of type 2 diabetes.

Cawthorne has a global reputation for his research into treatments for type 2 and obesity. As Group Director for diabetes and obesity research at SmithKline Beecham, he led the research team that developed the drug Avandia (rosiglitazone), a commercially successful insulin sensitizer.

GW's research on the use of cannabinoids in the treatment of type 2 has shown beneficial effects on levels of plasma insulin and on leptin and adiponectin, hormones that factor heavily in both the onset and the treatment of the disease. The research has also shown a reduction in overall levels of cholesterol, while increasing levels of "good" HDL cholesterol.

As a result, the company has developed two cannabinoid-based drugs that have passed through Phase 1 clinical trials: delta-9-tetrahydrocannabivarin (THCV) and cannabidiol (CBD). GW reports that CBD has demonstrated potential beneficial effects on non-fatty liver disease and hypercholesterolemia, the condition in which there is an abnormal amount of cholesterol in cells and blood plasma-often a precursor to artherosclerosis.

THCV's effects so far have included raising energy expenditure, a key element in blood glucose control. GW will combine both drugs in a Phase IIa trial of their effects in the treatment of fatty liver and dyslipidemia (disruption of lipid levels in the blood) in type 2 patients.

GW says the objectives of its alliance with Cawthorne include:

Providing GW with a dedicated facility for undertaking pre-clinical pharmacologic studies of cannabinoids in the area of metabolic disease
Providing GW with exclusive access to plant-based therapies under evaluation at the Clore Laboratory
Supporting the pharmaceutical development of new GW cannabinoid medicines to address defined aspects of metabolic syndrome
Getting expert advice from Cawthorne in the metabolic disease area

Categories: Blood Glucose, Complementary Therapies, Diabetes, Diabetes, Insulin, Research, Type 2 Issues

Comments

Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...

Registered User Anonymous

Your Name:	Your Email:	X

Recipient's Name:	Recipient's Email:

Your Chosen Username:	Your Email Address:

Chosen Password:	Confirm Password:

Email to a Friend

Dude! Marijuana Could Be the Basis for a Type 2 Drug

You May Also Be Interested In...

Comments

Register...

Have Your Say...

Diabetes Health

Topics

Topics

Topics

Diabetes Health Medical Disclaimer

Comment: